Enjoy complimentary customisation on priority with our Enterprise License!
Osteoarthritis is one of the chronic conditions for joints which results in the breakdown and eventual loss of the cartilage of one or more joints. This can affect joints including hips, lower back, neck, small joints of the fingers, and the base of the thumb and big toe. With the increasing awareness of osteoarthritis, the rise in diagnosis rates, the growing older population, and the increasing cases of obesity, the osteoarthritis market will witness considerable growth in the coming years. According to Technavio’s pipeline analysis report, most of the molecules under investigation are currenty in the early stages of development.
Our comparative analysis on the molecules in the pipeline for the stem cell therapy for osteoarthritis has identified that most of these molocules are in the pre-clinical, phase I, and phase II stages. GID Group’s GID SVF is in the phase III (pivotal) stage and the drug is based on GID technology. It is a monotherapy drug and can be administered through a single-use disposable device.
This pipeline analysis report has identified fourteen companies that are actively involved in the development of stem cell therapy for osteoarthritis. Based on the companies’ revenue, this report has segregated the players into Tier 1, Tier 2, and Tier 3 companies. One of the major Tier 1 companies Mesoblast, is a leading player in the biotechnology industry and registered a revenue of almost USD 43 million in 2016.
The Tier 1 companies covered in the are –
Monotherapy drugs are used to treat a particular disease. Our analysts have identified that all the stem cell therapy osteoarthritis drugs that are currently in the pipeline are being developed as a monotherapy agent.
Most of the companies currently involved in the stem cell therapy for osteoarthritis focus on the knee osteoarthritis segment. VivaTech International is the only company that si focusing on the shoulder, hip, and knee osteoarthritis.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.